Services
Regulatory & Clinical
Global regulatory pathway design, agency interaction strategy, and clinical program oversight for ophthalmic sponsors — from pre-IND and Scientific Advice through approval and post-marketing commitments.
Regulatory strategy in ophthalmology requires more than checklist submissions. Novel mechanisms, intravitreal administration, gene therapies, and combination products each carry distinct FDA and EMA expectations for nonclinical packages, clinical endpoints, and long-term follow-up.
BEEÑA-E designs pathway strategies that anticipate agency questions before they become delays. We conduct gap analyses against ophthalmic precedents, structure pre-IND, Type B/C, and Scientific Advice interactions, and prepare briefing packages with clear positions, supporting data, and fallback options.
Clinical oversight spans protocol design, statistical considerations, and operational feasibility for retina and anterior segment trials. We support DSMB charter input, enrollment risk mitigation, and cross-region harmonization when US and EU requirements diverge on endpoints or follow-up duration.
For sponsors managing multiple regions, we map parallel pathways across FDA, EMA, PMDA, and selected emerging markets — identifying where a single global protocol is viable and where local adaptations protect approval timelines without fragmenting the evidence base.
Key outcomes
- Global regulatory pathway assessments with agency-specific risk flags
- Briefing packages, Q&A preparation, and response strategies for formal meetings
- Protocol and amendment review aligned to ophthalmic regulatory precedent
- Combination-product and novel-delivery regulatory coordination (CMC + clinical)
- Post-approval commitment planning and lifecycle regulatory governance
Frequently asked questions
FDA, EMA, PMDA, and priority emerging markets. Our work is informed by ophthalmic precedents, published guidance, and direct interaction experience across retinal and anterior segment programs.
We routinely prepare briefing documents, anticipated questions, and response strategies. Meeting attendance is arranged based on sponsor preference, meeting format, and internal regulatory resourcing.
Yes. We address durability of effect, long-term safety follow-up, registry commitments, and access implications that often accompany retinal gene therapy approvals.
Related services
Next steps
Discuss regulatory & clinical priorities
Confidential consultation with senior advisors on your ophthalmic program.